Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Web Exclusives - FDA Approvals

On October 1, 2021, the FDA accelerated the approval of a new indication for brexucabtagene autoleucel (Tecartus; Kite Pharma), a CD19-directed CAR T-cell therapy, for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The FDA granted brexucabtagene autoleucel breakthrough therapy and orphan drug designations for this indication.

This approval was based on the ZUMA-3 study, a single-arm multicenter clinical trial of adults with relapsed or refractory B-cell precursor ALL. Patients received a single infusion of brexucabtagene autoleucel after completion of lymphodepleting chemotherapy.

The efficacy measures were complete response (CR) within 3 months after receiving the CAR T-cell infusion, and the duration of the CR. Of the 54 patients evaluable for efficacy, 28 (52%; 95% confidence interval, 38-66) achieved CR within 3 months. At a median follow-up of 7.1 months, the median duration of CR was not reached, and the duration of CR was estimated to be >12 months for >50% of the patients.

The most common (≥20%) nonlaboratory side effects included fever, cytokine-release syndrome, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.

Related Items
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
Web Exclusives published on July 29, 2022 in FDA Approvals
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
Web Exclusives published on July 22, 2022 in FDA Approvals
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
Web Exclusives published on July 19, 2022 in FDA Approvals
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
Web Exclusives published on July 19, 2022 in FDA Approvals
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
Web Exclusives published on May 26, 2022 in FDA Approvals
Last modified: February 16, 2022
Copyright © Engage Healthcare Communications, LLC. All rights reserved.